In the media
Recompensa a la audacia de Minoryx y Ability
Ability Pharma se refuerza en EEUU
AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812
Diari de Sabadell
The phase 2 of the antitumoral drug starts
Start of a clinical trial with a new drug for lung and endometiral cancer
La Vanguardia online
ABTL0812, from AbilityPharmaceuticals, is designed Orphan
European support to the oncology investigation
Siege to cancer from Bellaterra
L'Econòmic - El Punt Avui
Ability Pharma, 1.2 million to enter clinical phase.
Ability Pharma raises 1 million euros for a new drug.
Financing rounds of Catalan start-ups in 2012
AB-Therapeutics raises one million euros and becomes Ability Pharmaceuticals.
AB-Therapeutics closes a financing round.
AB-Therapeutics gets one million funding for new drug.
AB-Therapeutics closes a financing round of one million euros.
AB-Therapeutics obtains resources to move forward in its R&D in oncology.
AB-Therapeutics closes a financing round of one million Euros and changes its name to Ability Pharmaceuticals.
Diari de Sabadell
Abstract presented at the the meeting of the European Association for Cancer Research (AACR) in Barcelona (July 7-10, 2012)
Inveready Capital Company invests in AB-Therapeutics.
El Punt-Avui interviews Carles Domènech, the CEO of AB-Therapeutics.
NewsAbility Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
NewsAbility Pharmaceuticals launches a new updated website with a fresh design + info
NewsAbility Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
NewsAbility Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
NewsAbility Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
NewsAbility Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
NewsAbility Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
NewsABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
NewsAbility Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013. + info